Advertisement

Diagnostics particuliers

Chapter
  • 716 Downloads

Résumé

Déf.: La cytogénétique et l’hybridation fluorescente in situ (FISH) sont des méthodes utilisées pour déceler les anomalies chromosomiques clonales des cellules malignes → essentielles au diagnostic, à l’évaluation de la progression, du traitement et du pronostic des pathologies hématologiques.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Réf.

  1. 1.
    Bordeleau L, Berinstein NL. Molecular diagnostics in follicular non-Hodgkin’s lymphoma. Semin Oncol 2000;27(6 Suppl 12):42–52PubMedGoogle Scholar
  2. 2.
    Burmeister T, Thiel E. Molecular genetics in acute and chronic leukemias. J Cancer Res Clin Oncol 2001;127:80–90PubMedCrossRefGoogle Scholar
  3. 3.
    Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322–2333PubMedGoogle Scholar
  4. 4.
    Harrison CJ. The management of patients with leukaemia: the role of cytogenetics in this molecular era. Br J Hematol 2000;108:19–30CrossRefGoogle Scholar
  5. 5.
    Huret JL, Dessen P, LeMinor S et al. The “Atlas of Genetics and Cytogenetics in Oncology and Haematology” on the internet and a review on infant leukemias. Cancer Genet Cytogenet 2000;120:155–159PubMedCrossRefGoogle Scholar
  6. 6.
    Kristensen TD, Wesenberg F et al. High-resolution comparative genomic hybridisation yields a high detection rate of chromosomal aberrations in childhood acute lymphoblastic leukaemia. Eur J Haematol 2003;70:363–372PubMedCrossRefGoogle Scholar
  7. 7.
    Mrozek K, Heinonen K, Bloomfield CD. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int J Hematol 2000;72:261–271PubMedGoogle Scholar

Réf.

  1. 1.
    Cassinat B, Zassadowski F, Balitrand N et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 2000;14:324–328PubMedCrossRefGoogle Scholar
  2. 2.
    Krauter J, Pascheberg U, Heinze B et al. Detection of karyotypic aberrations in acute myeloblastic leukemia (AML): a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML. Br J Haematol 1998;103:72–78PubMedCrossRefGoogle Scholar
  3. 3.
    Perez EA, Pusztai L, Van de Vijver M. Improving patient care through molecular diagnostics. Semin Oncol 2004;31(5 Suppl 10):14–20PubMedCrossRefGoogle Scholar
  4. 4.
    Schoch C, Kohlmann A et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expressions profiles. Proc Natl Acad Sci U S A 2002;99:10008–10013PubMedCrossRefGoogle Scholar
  5. 5.
    Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003;348:1777–1785PubMedCrossRefGoogle Scholar
  6. 6.
    Varella-Garcia M. Molecular cytogenetics in solid tumors: laboratorial tool for diagnosis, prognosis, and therapy. Oncologist 2003;8:45–58PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Baak JPA, Path FRC, Hermsen MAJA et al. Genomics and proteomics in cancer. Eur J Cancer 2003;39:1199–1215PubMedCrossRefGoogle Scholar
  2. 2.
    Bullinger L, Döhner K, Bair E et al. Use of gene expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004;350:1605–1616PubMedCrossRefGoogle Scholar
  3. 3.
    Ebert BL, Golub TR. Genomic approaches to hematologic malignancies. Blood 2004;104:923–932PubMedCrossRefGoogle Scholar
  4. 4.
    Hubank M. Gene expression profiling and its application in studies of haematological malignancy. Br J Haematol 2004;124:577–594PubMedCrossRefGoogle Scholar
  5. 5.
    Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006; 354:2463–1472PubMedCrossRefGoogle Scholar
  6. 6.
    Ramaswamy S, Ross KN, Lander ES et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49–54PubMedCrossRefGoogle Scholar
  7. 7.
    Rosenwald AR, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947PubMedCrossRefGoogle Scholar
  8. 8.
    Van de Vijver MJ, He YD, van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999–2009PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Brawer MK. Prostate-specific antigen: current status. CA Cancer J Clin 1999;49:264–281PubMedCrossRefGoogle Scholar
  2. 2.
    Gion M, Mione R, Barioli P et al. Dynamic use of tumor markers: rationale, clinical applications and pitfalls. Anticancer Res 1996;16:2279–2284PubMedGoogle Scholar
  3. 3.
    Locker GY, Hamilton S, Harris J et al. ASCO 2006 Update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313–5327PubMedCrossRefGoogle Scholar
  4. 4.
    Rapkiewicz AV, Espina V, Petricoin EF et al. Biomarkers of ovarian tumours. Eur J Cancer 2004;40:2604–2612PubMedCrossRefGoogle Scholar
  5. 5.
    Scher HI, Eisenberger M, D’Amico AV et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen. Recommendations from the PSA Working Group. J Clin Oncol 2004;22:537–556PubMedCrossRefGoogle Scholar
  6. 6.
    Sölétormos G, Nielsen D, Schioler V et al. Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J Cancer 2004;40:481–486PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Bene M, Castoldi G, Knapp W et al. Proposals for the immunological classification of acute leukemias. Leukemia 1995;9:1783–1786PubMedGoogle Scholar
  2. 2.
    Bennett J, Catovskz D, Daniel M et al. Proposed revised criteria for the classification of acute myeloid leukemias. Ann Intern Med 1985;103:626–629CrossRefGoogle Scholar
  3. 3.
    Cheson B, Cassileth P, Head D et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813–819PubMedGoogle Scholar
  4. 4.
    Gratama JW, Sutherland DR, Keeney M. Flow cytometric enumeration and immunophenotyping of hematopoietic stem and progenitor cells. Semin Hematol 2001;38:139–147PubMedCrossRefGoogle Scholar
  5. 5.
    Harris NL, Jaffe E, Stein H et al. A Revised European-American Classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361–1392PubMedGoogle Scholar
  6. 6.
    Harris NL, Jaffe E, Stein H et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835–3849PubMedGoogle Scholar
  7. 7.
    Mason D et al (eds). Leucocyte Typing VII. Oxford University Press, 2001Google Scholar
  8. 8.
    Stetler-Stevenson M, Braylan RC. Flow cytometric analysis of lymphomas and lymphoproliferative disorders. Semin Hematol 2001;38:111–123PubMedCrossRefGoogle Scholar
  9. 9.
    Vardiman J, Harris NL, Brunning RD; the World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–2302PubMedCrossRefGoogle Scholar
  10. 10.
    Zola H, Swart B, Nicholson I et al. CD molecules 2005: Human cell differentiation molecules. Blood 2005;106:3123–3126PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Fisch P, Moris A, Rammensee HG et al. Inhibitory MHC class I receptors on gammadelta T cells in tumour immunity and autoimmunity. Immunol Today 2000;21:187–191PubMedCrossRefGoogle Scholar
  2. 2.
    Godsell DS. The molecular perspective: MHC. Oncologist 2005;10:80–81CrossRefGoogle Scholar
  3. 3.
    Klein J, Sato A. The HLA System. N Engl J Med 2000;243:702–709, 782–6Google Scholar
  4. 4.
    Marsh SG, Bodmer JG, Albert ED et al. Nomenclature for factors of the HLA system, 2000. Tissue Antigens 2001;57:236–283PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2011

Authors and Affiliations

There are no affiliations available

Personalised recommendations